论文部分内容阅读
目的 :探讨硫氮酮对阵发性心房颤动 (房颤 )的治疗效果。方法 :选择 6 2例阵发性房颤患者 ,随机分为硫氮酮组 (31例 )和对照组 (31例 ) ,随访 3年 ,观察房颤年发作次数、持续时间和转变为持续性房颤的情况。结果 :①硫氮酮明显减少房颤年发作次数、持续时间 (P <0 .0 1) ,但用药后 1～ 2年间差异无显著性意义(P >0 .0 5 ) ;②对照组房颤年发作次数、持续时间逐年增加 ,年与年之间差异有非常显著性意义 (P <0 .0 1) ;③随访期间 ,对照组有 6例而硫氮酮组无一例转变为持续性房颤 ,两组间差异有显著性意义 (P <0 .0 5 )。结论 :硫氮酮可明显减少阵发性房颤发作次数和持续时间 ,在阻止其转变为持续性房颤也有一定的作用 ,推测与硫氮酮阻止房颤电重构的发生有关
Objective: To investigate the therapeutic effect of diazinon on paroxysmal atrial fibrillation (atrial fibrillation). Methods: Sixty-two patients with paroxysmal atrial fibrillation were randomly divided into three groups: the thiazolidone group (n = 31) and the control group (n = 31). The patients were followed up for 3 years to observe the number of episodes and duration of atrial fibrillation Atrial fibrillation situation. Results: ①Diazarin significantly reduced the number and duration of episodes of atrial fibrillation (P <0.01), but there was no significant difference between 1 and 2 years after treatment (P> 0.05); ②The control group The number of episodes and the duration of atrial fibrillation increased year by year with significant difference between years (P <0.01). During the follow-up period, there were 6 cases in the control group and none in the diazinone group Persistent atrial fibrillation, the difference between the two groups was significant (P <0. 05). Conclusion: Azithromycin can significantly reduce the number and duration of episodes of paroxysmal atrial fibrillation, prevent its conversion to persistent atrial fibrillation also has a role, presumably with azathione to prevent the occurrence of atrial fibrillation